A practical reference on peptide hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
=== Prenatal diagnosis === Mutations in the main genes responsible for TCS can be detected with chorionic villus sampling or amniocentesis. Rare mutations may not be detected by these methods. Ultrasonography can be used to detect craniofacial abnormalities later in pregnancy, but may not detect milder cases.
Therefore, ketone bodies are a way to move energy from the liver to other cells. The liver does not have the critical enzyme, succinyl CoA transferase, to process ketone bodies, and therefore cannot undergo ketolysis. The result is that the liver only produces ketone bodies, but does not use a significant amount of them.
Members of parliament refers to the elected members of the Riksdag. In Swedish, an MP is usually referred to as a riksdagsledamot (member of the Riksdag) or a riksdagsman (gentleman of the Riksdag). The former is in more common use today, especially in official contexts, due to its status as a unisex word, while the latter was used more often historically and literally refers to a male MP exclusively. The parliament is a unicameral assembly with 349 members who are chosen every four years in general elections. To become an MP, a person must be entitled to vote (i.e. be a Swedish citizen, be at least 18 years old and be or have been resident in Sweden) and must be nominated by a political party. The MPs are elected by proportionality in constituencies across the nation. To decide which candidate will be elected the modified Sainte-Laguë method is used. This method usually but not always gives an accurate result in proportion to cast votes. The salaries of the MPs are decided by the Riksdag Pay Committee (Riksdagens arvodesnämnd), a government agency under the Riksdag. Since 1 November 2007, the basic monthly pay of an MP is SEK52,900 (ca. US$6,500). The pay of the speaker is SEK126,000 a month (ca. US$15,000), which is the same as that of the prime minister. The deputy speakers receive an increment of 30% of the pay of a member. The chairs and deputy chairs of the parliamentary committees receive a similar increment of 20% and 15% respectively.
== Early life and education == Namandjé Bumpus was born in Philadelphia and raised in western Massachusetts. She became interested in chemistry at a young age, even writing to the American Chemical Society while still in elementary school to ask about the kind of careers chemists can have. She earned a B.A. in Biology from Occidental College, in Los Angeles, California, in 2003. At Occidental, she was introduced to research experiences in ecology, then she ventured into pharmacology through Charles Ross Summer Research Fellowship at the University of Michigan, during which she was mentored by Dr. Richard R. Neubig. She enjoyed the experience so much that she decided to return to the University of Michigan after graduating from Occidental College in order to pursue a PhD in pharmacology. She earned her Ph.D. in pharmacology from the University of Michigan Medical School in 2007. Her thesis research, and much of her later work, examined how drugs are processed by cytochrome P450 enzymes, (CYPs) a family of heme-containing monooxygenases, that often help make drugs more soluble, aiding with drug clearance. Bumpus performed her thesis research in the laboratory of Dr. Paul F. Hollenberg, investigating how a naturally occurring mutation in CYP2B6 affects its ability to be inactivated by compounds known the inactivate the wild-type CYP2B6. She also looked into how naturally occurring variants could impact how patients cleared the antidepressant Bupropion, and the antiviral Efavirenz.
Sources: en.wikipedia.org
=== Early speculation === The possibility of a seventh noble gas, after helium, neon, argon, krypton, xenon, and radon, was considered almost as soon as the noble gas group was discovered. Danish chemist Hans Peter Jørgen Julius Thomsen predicted in April 1895, the year after the discovery of argon, that there was a whole series of chemically inert gases similar to argon that would bridge the halogen and alkali metal groups: he expected that the seventh of this series would end a 32-element period which contained thorium and uranium and have an atomic weight of 292, close to the 294 now known for the first and only confirmed isotope of oganesson. Danish physicist Niels Bohr noted in 1922 that this seventh noble gas should have atomic number 118 and predicted its electronic structure as 2, 8, 18, 32, 32, 18, 8, matching modern predictions. Following this, German chemist Aristid von Grosse wrote an article in 1965 predicting the likely properties of element 118. It was 107 years from Thomsen's prediction before oganesson was successfully synthesized, although its chemical properties have not been investigated to determine if it behaves as the heavier congener of radon. In a 1975 article, American chemist Kenneth Pitzer suggested that element 118 should be a gas or volatile liquid due to relativistic effects.
=== Correlates === A variety of studies have examined the relationship between health behaviors and health outcomes (e.g., Blaxter 1990) and have demonstrated their role in both morbidity and mortality. These studies have identified seven features of lifestyle which were associated with lower morbidity and higher subsequent long-term survival (Belloc and Breslow 1972):
NOS Journaal – one of the most important news programmes in the Netherlands, broadcast on all public stations whenever possible. The flagship edition is the 8 pm bulletin on NPO 1, often called achtuurjournaal, supplemented by two shorter editions at 6pm & midnight and hourly bulletins throughout the day. NOS Jeugdjournaal – A news programme aimed at 8–12-year-olds, aired on children's channel NPO Zapp. It is broadcast at 7pm and lasts 20 minutes, and a short bulletin is broadcast every weekday at 8:45 am when primary school starts. NOS Studio Sport – A sports programme covering the most popular sports. It has the right to broadcast major sports tournaments, like the Olympic Games and the FIFA World Cup and UEFA Euro. The NOS no longer has the right to broadcast full matches of the Eredivisie, but Studio Sport Eredivisie still provides summaries of matches played. The programme also covers matches and competitions in other sports, most notably tennis, ice skating, cycling, and field hockey. The editorial staff is also responsible for the NOS Sportjournaal, a news programme about sport, and NOS Studio Voetbal, a football talkshow on Sunday evening about the Eredivisie, the Netherlands national team and other news in football. NOS Journaal op 3 – a 60-second news bulletin aimed at teenagers and young adults, aired on NPO 3, since 2011 called NOS op 3. NOS Den Haag Vandaag – a daily roundup of events from parliamentary sessions and political reports, produced in cooperation with the NOS, NTR and BNNVARA.
Sources: en.wikipedia.org
=== Metabolism === Strychnine is rapidly metabolized by the liver microsomal enzyme system requiring NADPH and O2. Strychnine competes with the inhibitory neurotransmitter glycine resulting in an excitatory state. However, the toxicokinetics after overdose have not been well described. In most severe cases of strychnine poisoning, the patient dies before reaching the hospital. The biological half-life of strychnine is about 10 hours.
parietina, including its apothecial margins and hymenia. Unlike A. molendoi (which primarily infects Rusavskia elegans), A. parietinaria appears to be restricted to the X. parietina group and is widespread throughout Europe, western Asia, and northern Africa. The fungus acts as a commensal or weakly parasitic species, causing no significant destruction of host tissue outside infection spots, though larger groups of ascomata may cause slight discoloration of the host thallus. The biochemical impact of the lichenicolous fungus Xanthoriicola physciae on its host has been investigated using Raman spectroscopy. This technique revealed that the fungus destroys key photoprotective pigments—such as parietin and carotenoids—that are vital for shielding the lichen from intense sunlight. Additionally, the detection of scytonemin—a pigment typically produced by cyanobacteria and known for UV protection—in the infected tissues implies secondary colonisation by cyanobacteria.
Further, the method lacks the capability to distinguish between positive and negative nonsynonymous substitutions. Some amino acids are chemically similar to one another, whereas other substitutions may place an amino acid with wildly different properties to its precursor. In most situations, a smaller chemical change is more likely to allow the protein to continue to function, and a large chemical change is likely to disrupt the chemical structure and cause the protein to malfunction. However, incorporating this into a model is not straightforward as the relationship between a nucleotide substitution and the effects of the modified chemical properties is very difficult to determine. An additional concern is that the effects of time must be incorporated into an analysis, if the lineages being compared are closely related; this is because it can take a number of generations for natural selection to "weed out" deleterious mutations from a population, especially if their effect on fitness is weak. This limits the usefulness of the Ka/Ks ratio for comparing closely related populations.
The short half-life and limited penetrating power of alpha radiation through tissues offers advantages in situations where the "tumor burden is low and/or malignant cell populations are located in close proximity to essential normal tissues." Significant morbidity in cell culture models of human cancers has been achieved with from one to ten astatine-211 atoms bound per cell.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.